STOCK TITAN

Allogene Therapeutics, Inc. - ALLO STOCK NEWS

Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer and autoimmune diseases. Leveraging the expertise of former Kite Pharma executives, Allogene aims to revolutionize cancer treatment with innovative off-the-shelf CAR T solutions. These therapies, derived from healthy donor cells, provide a scalable and readily available option, eliminating the lengthy and complex process of personalized cell therapy.

The company's portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy in phase 1 development for acute lymphoblastic leukemia (ALL). Notable core programs target various malignancies such as lymphoma, leukemia, solid tumors, and autoimmune diseases. Among its leading investigational products is cemacabtagene ansegedleucel (cema-cel), currently undergoing pivotal phase 2 ALPHA3 trials for large B-cell lymphoma (LBCL) and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL). ALLO-316, aimed at renal cell carcinoma (RCC), and ALLO-329, targeting autoimmune diseases with Dagger® technology, further strengthen Allogene's robust pipeline.

Allogene collaborates with leading biotech firms like Foresight Diagnostics and Arbor Biotechnologies to enhance its clinical development capabilities. Recent achievements include strategic partnerships and a $15 million grant from the California Institute for Regenerative Medicine (CIRM) supporting the development of ALLO-316. Financially, Allogene reported a strong cash runway extending into 2026, with latest funding rounds ensuring continued support for its R&D initiatives.

Stay informed on Allogene's progress as it drives the future of allogeneic CAR T therapy, providing broader patient access and more efficient cancer treatment options.

Rhea-AI Summary

Allogene Therapeutics (ALLO) announced significant developments in its clinical initiatives, including anticipated U.S. FDA clearance for the Phase 2 pivotal trial of ALLO-501A targeting relapsed/refractory large B cell lymphoma (LBCL). This trial could be a first for allogeneic CAR T therapies. The company’s manufacturing facility, Cell Forge 1, is expected to produce approximately 20,000 doses annually. As of June 30, 2022, Allogene reported $686 million in cash and a net loss of $74.8 million for Q2 2022, with increased spending expected in the second half of the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
-
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company, announced its participation in three upcoming investor conferences. These include the 42nd Annual Canaccord Genuity Growth Conference on August 11, 2022, the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, and the Baird 2022 Global Healthcare Conference on September 13, 2022. Allogene is focused on developing allogeneic CAR T products for cancer treatment. Webcasts of the presentations will be available on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.87%
Tags
conferences
-
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO) will announce its second quarter 2022 financial results on August 9, 2022, after market close. A conference call and live audio webcast will follow at 2 PM PT/5 PM ET. The webcast can be accessed on the company's website, with a replay available for 30 days. Allogene focuses on developing AlloCAR T™ products to provide accessible cell therapy for cancer patients. This initiative aims to enhance the reliability and scalability of treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
conferences earnings
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO) has appointed Stephen L. Mayo, Ph.D., an expert in computational protein design, to its Board of Directors. Mayo has extensive experience in both academia and the biopharmaceutical sector, which is expected to benefit Allogene as it advances its AlloCAR T product pipeline. Mayo's background includes leadership roles at Caltech and co-founding several biotech companies. His appointment is aimed at enhancing the company's ability to deliver innovative cell therapies to cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
management
-
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO) announced the FDA granted RMAT designation to ALLO-501A for patients with relapsed/refractory large B cell lymphoma (LBCL). This recognition follows positive results from the ALPHA2 trial, demonstrating safety and durable responses. Treatment initiation occurs within two days, enhancing patient access. The company plans to start a Phase 2 pivotal trial in mid-2022. The RMAT designation aims to expedite the development of ALLO-501A, which aims to meet critical patient needs lacking effective therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.22%
Tags
none
-
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO) presented preclinical findings indicating that allogeneic CAR T cells derived from younger, healthy donors exhibit significantly improved fitness and anti-tumor potential compared to those from older donors and cancer patients. This research suggests such cells could mitigate manufacturing failures common in autologous therapies. The study was shared at the 2022 ASGCT Annual Meeting, emphasizing the promise of developing reliable, off-the-shelf CAR T therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
Rhea-AI Summary

Allogene Therapeutics, Inc. (Nasdaq: ALLO) has been ranked as the top biotechnology company on the 2022 Best Places to Work list by the San Francisco Business Times and the Silicon Valley Business Journal. This recognition is based on employee surveys evaluating engagement, communication, and team dynamics among other factors, highlighting a strong workplace culture. CEO David Chang emphasized the importance of employee feedback in achieving this accolade. Allogene, which focuses on developing allogeneic CAR T therapies, actively seeks to expand its workforce.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.15%
Tags
none
-
Rhea-AI Summary

Allogene Therapeutics (NASDAQ: ALLO) updated its corporate progress and financial results for Q1 2022, reporting a net loss of $79.9 million, or $0.56 per share, with cash reserves of $733 million as of March 31, 2022. The pivotal Phase 2 ALPHA2 trial for ALLO-501A in relapsed/refractory large B-cell lymphoma is anticipated to commence mid-2022, supported by the newly operational Cell Forge 1 manufacturing facility, capable of producing approximately 20,000 doses annually. The company also received FDA Orphan Drug Designation for ALLO-605, its first TurboCAR product candidate for multiple myeloma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
-
Rhea-AI Summary

Allogene Therapeutics has appointed Susan Lundeen as the new Chief People Officer, effective May 2, 2022, in a role designed to enhance their human resources strategy as the company prepares for pivotal trials and expands its AlloCAR T pipeline. Lundeen brings extensive experience from previous roles at Unity Biotechnology and Kythera Biopharmaceuticals. Allogene, a leader in allogeneic cell therapy, currently employs over 320 staff and aims to foster a competitive and inclusive workforce to drive its growth trajectory in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
management
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO) will announce its first-quarter 2022 financial results on May 4, 2022, after market close. Following the announcement, a live audio webcast and conference call will take place at 2:00 PM PT/5:00 PM ET. The webcast can be accessed on the company’s website under the Investors tab, with a replay available for 30 days. Allogene focuses on developing allogeneic CAR T products for cancer treatment, aiming to provide accessible and reliable therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences earnings

FAQ

What is the current stock price of Allogene Therapeutics (ALLO)?

The current stock price of Allogene Therapeutics (ALLO) is $1.87 as of December 20, 2024.

What is the market cap of Allogene Therapeutics (ALLO)?

The market cap of Allogene Therapeutics (ALLO) is approximately 393.1M.

What is Allogene Therapeutics, Inc.?

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of allogeneic CAR T therapies for cancer and autoimmune diseases.

What are Allogene's core products?

Allogene's core products include UCART19, cemacabtagene ansegedleucel (cema-cel), ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune diseases.

What is unique about Allogene's therapies?

Allogene's therapies are off-the-shelf CAR T products derived from healthy donor cells, providing scalable and readily available treatment options.

Who are Allogene's key partners?

Allogene collaborates with biotech firms like Foresight Diagnostics and Arbor Biotechnologies to enhance its clinical development capabilities.

In which clinical trials is cema-cel involved?

Cema-cel is involved in the pivotal phase 2 ALPHA3 trial for large B-cell lymphoma (LBCL) and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL).

What recent financial achievement did Allogene secure?

Allogene received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the development of its ALLO-316 product.

How does Allogene's financial outlook appear?

Allogene reported a strong cash runway extending into 2026, bolstered by recent funding rounds to support continued research and development efforts.

What is the focus of Allogene's ALLO-316 trial?

The ALLO-316 trial focuses on advanced or metastatic renal cell carcinoma (RCC), assessing the safety, tolerability, and preliminary efficacy of the therapy.

What is the Dagger® technology used in ALLO-329?

Dagger® technology is used in ALLO-329 to eliminate the need for lymphodepletion while targeting CD19+ B-cells and CD70+ activated T-cells in autoimmune diseases.

What is the goal of Allogene's therapies?

Allogene aims to provide broadly accessible, scalable, and efficient cancer and autoimmune disease treatments through its pioneering allogeneic CAR T therapies.

Allogene Therapeutics, Inc.

Nasdaq:ALLO

ALLO Rankings

ALLO Stock Data

393.14M
145.68M
17.43%
80.22%
16.72%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO